Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Abstract Background Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15–50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-asso...

Full description

Bibliographic Details
Main Authors: Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland, on behalf of the Antibacterial Resistance Leadership Group (ARLG)
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Trials
Subjects:
Staphylococcus aureus
Bacteremia
Right-sided endocarditis
Dalbavancin
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06370-1

Internet

https://doi.org/10.1186/s13063-022-06370-1

Similar Items